Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study

  • Jukka Pulkkinen1, 2Email author,

    Affiliated with

    • Matti Eskelinen1, 2,

      Affiliated with

      • Vesa Kiviniemi3,

        Affiliated with

        • Tuukka Kotilainen2,

          Affiliated with

          • Markus Pöyhönen2,

            Affiliated with

            • Lasse Kilpeläinen2,

              Affiliated with

              • Pirjo Käkelä1, 2,

                Affiliated with

                • Helena Kastarinen3 and

                  Affiliated with

                  • Hannu Paajanen1, 2

                    Affiliated with

                    BMC Gastroenterology201414:119

                    DOI: 10.1186/1471-230X-14-119

                    Received: 25 April 2014

                    Accepted: 26 June 2014

                    Published: 3 July 2014

                    Abstract

                    Background

                    Statins can modify bile cholesterol and, thus, the formation of gallstones. We examined whether statin use also modifies the severity of symptomatic gallstone disease and its treatment.

                    Methods

                    A total of 1,140 consecutive patients with symptomatic gallstone disease were recruited during 2008-2010 at Kuopio university hospital, Finland. Case-control analysis matched the patients using (n = 272) or not using (n = 272) statins by age and sex. The baseline characteristics of the patients, need and type of surgical treatment, duration of operation, perioperative bleeding, postoperative complications and overall mortality rate were compared statistically between the study groups.

                    Results

                    Morbidity and subsequent polypharmacy occurred more frequently among the patients with statins compared to the patients without statins. There were no significant differences between the statin users and non-users regarding surgical treatment (open vs. laparoscopic cholecystectomy). The mean operation time for laparoscopic cholecystectomy was 10% shorter for the patients with statin use than for the patients without. In addition, there was a non-significant tendency for statin users to bleed less during laparoscopic operations than the non-users. There were no differences in other procedure-related parameters (e.g., operation urgency, conversions, choledochotomies, complications and mortality) in patients with or without statins.

                    Conclusions

                    Compared to no treatment, statin treatment was associated with a shorter operation time for laparoscopy cholecystectomy. Other surgical outcome parameters were similar in patients with or without statins, although statin users had more polypharmacy and circulatory illnesses than non-users.

                    Keywords

                    Cholelithiasis Statins Cholecystectomy

                    Background

                    Gallstone disease and cholesterol-lowering statin medications are common in Western countries, and they have a high economic impact [1]. Symptomatic gallstones are one of the leading causes of inpatient admissions in general surgery [2]. The prevalence of gallstone disease is increasing because of worldwide epidemics of obesity, insulin resistance and aging. In Western populations, the majority of gallstones formed in the gallbladder consist mainly of cholesterol, as they are formed from cholesterol-supersaturated bile [3]. Cholesterol gallstones account for 80-95% of the gallstones found during cholecystectomy [4, 5].

                    Hypercholesterolemia is an important risk factor for atherosclerosis, which has been the most common cause of death in developed countries. Statins are used to treat dyslipidemia, which prevents cardiovascular or cerebrovascular events. Statins are among the most widely used medications in the Western world [6, 7]. As in other Western societies, statin use in Finland has increased exponentially: There has been an 11-fold increase in statin use between 1995 and 2005 [8]. According to the reimbursement register data of the Social Insurance Institute of Finland (population 5.2 million), approximately 660,000 individuals purchased statins in 2012, which is 12% of population.

                    The relationship between statins and symptomatic gallstone disease is still more or less conflicting, although several studies have reported a significant reduction in the incidence of symptomatic gallstones disease in patients using statin therapy [9]. The most consistent evidence is that bile is desaturated of cholesterol after the long-term administration of statins [10, 11]. These observations suggest that statins may reduce the size of cholesterol particles and, subsequently, prohibit gallstone formation and reduce the size of gallstones; therefore, they may also affect the course of symptomatic gallstone disease. The effect of statin therapy on the course and outcome of cholecystectomy is unknown.

                    We conducted a case control study to assess the influence of statins on complicated gallstone disease. Based on the effect of statins on gallstone formation, we hypothesized that statin use would be associated with less severe acute gallbladder inflammation, fewer stones in the common bile duct and, furthermore, fewer complications.

                    Methods

                    A total of 1,140 consecutive patients with symptomatic gallstones were admitted to Kuopio University Hospital, Finland, from 2008-2010. The hospital serves an area of 243,000 inhabitants. A total of 272 of 1,140 patients with symptomatic cholelithiasis underwent statin therapy. The age- and sex-matched controls (n = 272) were randomly selected from the cohort of patients without statin therapy. Patient data were obtained from the hospital records using the following discharge diagnoses (ICD 10): K80 (cholelithiasis), K81 (cholecystitis), K82 (other disease of gallbladder) or K83 (other diseases of biliary tract). The imaging study results (i.e., computed tomography, abdominal ultrasound, magnetic resonance cholangiography) were analyzed. Additional work-ups included a detailed clinical history with records of recent infectious diseases, abdominal traumas, surgery, and endoscopic retrograde cholangiopancreatography (ERCP), as well as data concerning comorbidities and medicine use on arrival. The laboratory data included serum calcium, lipids, liver enzymes and C-reactive protein measurements. The duration of hospital stay, need for intensive care treatment and one-month hospital mortality (2008-2010) were recorded. Data concerning the treatment type (e.g., conservative, laparoscopic, open surgery, conversions, cholecystostomy, and choledochotomies), surgical durations, elective vs. emergency operations, complications, bleeding and number of re-operations were collected from the patients records.

                    Surgery was performed in both study groups using the same operative principles and by the same group of surgeons. There were no between-group differences in the preoperative or perioperative treatments or procedures. Emergency cholecystectomy was performed if ultrasonography or clinical examination and laboratory parameters revealed signs of cholecystitis in and if the patient was suitable for operation, according to the American Society of Anesthesiologists physical status classification system. If possible, perioperative cholangiography was always performed in acute cholecystitis. Cholecystectomy was primarily performed laparoscopically. In patients with very old age and severe comorbidities, percutaneous cholecystostomy was performed. In patients with long histories of cholecystitis symptoms, the treatment was first conservative, and elective laparoscopy was performed later. According to the Finnish legislation, no ethical assessment or approval is mandatory for a register-based study. As this is a retrospective register study, informed consent from the patients was not needed.

                    Data were analyzed using IBM SPSS (Statistical Package for the Social Sciences) Statistics 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp. USA), and the statistical analyses were performed using independent samples t-tests, Mann-Whitney U-tests and χ2 tests, depending on the distribution of the outcome and distributional assumptions. Adjusted analyses of outcomes were not conducted because of the relatively small number of events in various outcomes of interest. P values less than 0.05 were considered to be statistically significant.

                    Results

                    A total of 1140 admissions of the patients with symptomatic cholelithiasis were recorded at our hospital between 2008 and 2010. There were 715 females and 425 males (63% and 37%, respectively). Some 272 patients used statins (24% of the whole study population), 132 females and 140 males (17.6% and 32.9%, respectively), (Table 1). The patients using statin therapy were, on average, older, had a greater incidence of type II diabetes and cardiovascular diseases and were more frequently male than the patients without statin therapy (data not shown).
                    Table 1

                    Demographic data of statin users (n = 272) and non-statin users (n = 272) patients with gallstones

                     

                    Statin users (n = 272)

                    No statin (n = 272)

                    P-value

                    Females/males

                    132/140 (48%/52%)

                    132/140 (48%/52%)

                    1.000

                    Age (years)

                    69 ± 11 (36-93)

                    69 ± 11 (36-93)

                    0.786

                    Body mass index (Kg/m2)

                    29 ± 4.2

                    28 ± 4.9

                    0.499

                    Use of statins

                       

                      Simvastatin

                    73%

                    199

                     

                      Atorvastatiini

                    13%

                    36

                     

                      Rosuvastatin

                    6%

                    15

                     

                      Fluvastatin

                    4%

                    11

                     

                      Pravastatin

                    2%

                    5

                     

                      Lovastatin

                    1%

                    3

                     

                      Other1

                    1%

                    3

                     

                    Comorbid condition

                       

                      Hypertension

                    161 (59%)

                    115 (42%)

                    < 0.001

                      Diabetes

                    48(18%)

                    38 (14%)

                    0.290

                    Coronary artery disease/

                       

                    Coronary heart failure/

                       

                      Valvular

                    151 (56%)

                    71 (26%)

                    < 0.001

                      Neurological

                    50 (18%)

                    48 (18%)

                    0.456

                      Psychiatric

                    16 (6%)

                    22 (8%)

                    0.401

                      Pulmonary

                    32 (12%)

                    37 (14%)

                    0.303

                      Rheumatoid

                    12 (4%)

                    12 (4%)

                    1.000

                      Malignancy

                    26 (10%)

                    33 (12%)

                    0.408

                    Number of medication

                       

                      No

                    0

                    75 (28%)

                     

                      1-3 drug

                    44 (16%)

                    88 (32%)

                     

                      > 4 drugs

                    228 (84%)

                    109 (40%)

                     

                    1Means combination of statin with other cholesterol-lowering drugs (fenofibrate, ezetimibe).

                    Values are presented as number (percentage) or mean (SD, min-max), as appropriate.

                    Statin users vs. their matched controls

                    In the case control comparison, hypertension and cardiac diseases were observed more frequently among the statin users compared with the non-users (Table 1). On the contrary, the prevalence of diabetes, neurological, psychiatric, and pulmonary diseases, as well as malignancy, were similar in both study groups. The mean BMI was similar between the groups. In the statin group, simvastatin constituted 73% and atorvastatin 13% of all statins (Table 1).

                    We also calculated the number of regularly used drugs in both groups. Polypharmacy (>4 medicines) was observed in more than 80% of the patients in the statin group and in 48% of the patients in the no-statin group (p < 0.001). In the non-use group, 28% of the patients were not using any medicines upon admission (data not shown).

                    We did not observe any statistically significant between-group differences in any of the assessed laboratory parameters, including LDL cholesterol. The mean C-reactive protein concentration was 112 mg/l in the statin group and 113 mg/l in the no-statin group (Table 2).
                    Table 2

                    Laboratory data of study groups

                     

                    Statin use (n = 272)

                    No statin (n = 272)

                    p-value

                    P-Amyl U/l

                    76 (166)

                    113 (478)

                    0.873

                    P-Afos U/l

                    134 (148)

                    131 (132)

                    0.924

                    P-Bil umol/l

                    24 (31)

                    30 (42)

                    0.171

                    ALAT U/l

                    89 (141)

                    108 (181)

                    0.639

                    fP-Kol-LDL mmol/l

                    2.2 (1.0)

                    2.4 (1.0)

                    0.622

                    fP-TRIG mmol/l

                    1.6 (0.9)

                    1.5 (0.8)

                    0.805

                    CRP mg/l

                    112 (100)

                    113 (111)

                    0.604

                    Values are expressed as mean (SD).

                    p-values are indicated using the Mann-Whitney U-test.

                    Approximately 27% of patients in the statin group and 25% of patients in the non-statin group were treated conservatively (Table 3). Approximately 68% of all operations were elective, and 32% were emergency procedures. Three quarters of the operations were started with laparoscopy. The mean conversion rate to open surgery was 13%. One patient in the non-statin group was re-operated two times: first because of bile leak and again because of abscesses. We found no significant differences between the statin users and non-users regarding the treatment types (elective/emergency, laparoscopic/open) or in the number of conversions or ERCP procedures (Table 3). Furthermore, there were no significant differences in the rate of complications, need for intensive care treatment or hospital mortality. Interestingly, the hospital mortality rates were similar among the statin users and the non-users (Table 3).
                    Table 3

                    Treatment and outcome of patients with cholelithiasis

                     

                    Statin use (n = 272)

                    No statin (n = 272)

                    p-value

                    Overall mortality

                    12 (4%)

                    19 (7%)

                    0.195

                    ICU treatment (N patients)

                    6 (2%)

                    3 (1%)

                    0.348

                    Mean hospital stay, days

                    4.3 ± 9.9

                    3.9 ± 4.7

                    0.7301

                    Treatment type

                       

                    Conservative/Surgical

                    73/199 (27/73%)

                    68/204 (25/75%)

                    0.625

                    Elective/emergency operation

                    138/61 (69/31%)

                    136/68 (67/33%)

                    0.769

                      Laparoscopic

                    131 (65%)

                    130 (64%)

                    0.659

                      Open surgery

                    47 (24%)

                    46 (23%)

                    0.799

                      Conversion

                    13 (7%)

                    17 (8%)

                    0.491

                      Cholecystostoma

                    8 (4%)

                    11 (5%)

                    0.516

                    Reoperations

                    6 (3.0%)

                    3 (1.5%)

                    0.211

                    Choledochotomy

                    13 (7%)

                    20 (10%)

                    0.197

                    Choledocholithiasis

                    9 (5%)

                    20 (10%)

                    0.104

                    Complications (operated)

                    27 (13.6%)

                    32 (15.7%)

                    0.733

                      Urological

                    5 (2.5%)

                    7 (3.4%)

                     

                      Peritonitis

                    3 (1.5%)

                    3 (1.5%)

                     

                      Bleeding

                    4 (2.0%)

                    3 (1.5%)

                     

                      Bile leak

                    3 (1.5%)

                    1 (0.5%)

                     

                      Other abscess

                    1 (0.5%)

                    1 (0.5%)

                     

                      Heart complication

                    1 (0.5%)

                    1 (0.5%)

                     

                      Lung complication

                    1 (0.5%)

                    0

                     

                      Other

                    9 (4.5%)

                    16 (7.8%)

                     

                    ERCP (all)

                    31 (11%)

                    34 (13%)

                    0.595

                    Values are shown as number (percentage) or mean (SD) unless otherwise indicated.

                    1Indicates the Mann-Whitney U-test.

                    In both study groups, open surgery was more often conducted as an emergency procedure compared with laparoscopic surgery (Table 4).
                    Table 4

                    Outcome of cholelithiasis in open and laparoscopic surgery

                     

                    Statin use (n = 272)

                    No statin (n = 272)

                    p-value

                    Surgery (laparoscopic and open)

                    N = 178

                    N = 176

                     

                    Laparoscopic

                    131 (74%)

                    130 (74%)

                     

                    Elective/Emergency

                    116/15 (89%/11%)

                    109/21 (84%/16%)

                    0.271

                      Mean operation time

                    71.4 ± 31.5

                    80.81 ± 39.2

                    0.042

                      Mean bleeding

                    20.8 ± 79.2

                    32.6 ± 88.1

                    0.070

                      Bleeding over 100 ml

                    7 (5%)

                    14 (11%)

                    0.099

                      Mean hospital stay, days

                    3.1 ± 13.5

                    2.2 ± 3.4

                    0.6001

                    Proportion of patients

                       

                    with more than 3 hospital days

                    42 (32%)

                    46 (35%)

                    0.602

                    Proportion of patients

                       

                    with more than 5 hospital days

                    13 (10%)

                    10 (8%)

                    0.525

                    Open surgery (conversions excl.)

                    47 (26%)

                    46 (26%)

                     

                    Elective/Emergency

                    14/33 (30%/70%)

                    15/31 (33%/67%)

                    0.769

                      Mean operation time

                    92.9 ± 38.1

                    104.8 ± 49.2

                    0.248

                      Mean bleeding

                    208.2 ± 275.1

                    229.5 ± 276.0

                    0.332

                      Bleeding over 100 ml

                    20 (43%)

                    18 (39%)

                    0.960

                      Mean hospital stay

                    6.1 ± 4.2

                    6.4 ± 6.5

                    0.788

                    Proportion of patients with more than 5 hospital days

                    28 (60%)

                    25 (54%)

                    0.611

                    Data are shown as mean (SD) or (percentage) unless otherwise indicated.

                    1Indicates the Mann-Whitney U-test.

                    Interestingly, the mean time for laparoscopic operations was 9.4 minutes shorter in the statin group compared with the control group (p = 0.042). In addition, the time needed for open surgery was shorter in the statin group compared with the non-statin group, although this difference was not statistically significant. Likewise, there was a non-significant trend of increased bleeding among the non-statin group.

                    Logistic regression analysis was used to adjust for age, gender and outcomes. The results did not differ from the unadjusted results presented in Table 4. Overall, the number of patients having outcomes was too small to conduct more extensive adjusted analyses (i.e., adjusting for co-morbidities). All open and converted patients remained, on average, three days longer in the hospital than the laparoscopic patients (mean 5.8 ± 5.0 and 2.6 ± 9.9, respectively, P < 0.001). There were no between-group differences regarding the hospitalization time (Table 4).

                    Discussion

                    The main finding of the present study was that the patients using statins did not have worse outcomes after cholecystectomy than the non-users, although the statin users were older, had polypharmacy and demonstrated more comorbidities than the non-users. Statin therapy was also associated with a shorter laparoscopic operation time. There was also a trend of other benefits from statin use for surgical outcomes, such as less bleeding. These findings are of clinical importance, as one would anticipate that statin users would have more post-surgical complications than non-users. A well-conducted prospective randomized study to show the possible benefits of statins in cholecystectomy is warranted.

                    The risk of developing symptoms or complications related to gallstones is approximately 1–4% per year [12, 13]. The known risk factors for gallstones are female gender, increasing age, obesity, metabolic syndrome, rapid weight loss and gallbladder stasis [14, 15]. The most important complications of the gallstone disease are biliary pancreatitis, cholecystitis and cholangitis. Festi et al. showed that during follow-up, approximately 80% of gallstones remain asymptomatic, 10% develop mild symptoms, and 10% develop severe symptoms leading to cholecystectomy [16]. The development of the symptomatic gallstones is associated with obesity and alcohol use, likely because of their effects on serum lipids [17]. It is presently unknown whether statin therapy would transform asymptomatic cholelithiasis to symptomatic.

                    The use of statins and other lipid-lowering drugs has been greatly increasing in Finland in recent years [8]. This increase has occurred particularly among elderly patients with hypercholesterolemia [18]. Prior to beginning our study, we anticipated that statin users would have less severe acute gallbladder inflammation, fewer stones in the common bile duct and more frequent laparoscopic cholecystectomy than non-users; this hypothesis proved wrong. Statins reduce the bile cholesterol content, which may theoretically reduce the risk of developing micro-gallstones or sludge. In the present study, the 1-year incidence of symptomatic cholelithiasis was approximately 0.22% among statin users and 0.14% among non-statin users (these calculations are based on reimbursement register data, data not shown).

                    Bodmer et al. performed a case control study using a UK-based database of approximately 5 million patients to investigate statins and the reduced risk of gallstone disease. In this large observational study, a lower incidence of cholecystectomy was noted in patients taking statins [3]. In addition, Tsai et al. performed a large retrospective cohort study among 2479 American women who had histories of gallstones. The authors found that statin use was associated with a reduced risk of cholecystectomy [10]. Smith et al. observed that simvastatin (20 mg/day) decreased plasma and biliary cholesterol levels by reducing cholesterol synthesis after 3 weeks of medication [19]. A long-term study in prairie dogs found that lovastatin alters biliary lipid composition and dissolves gallstones [20]. However, most human studies did not find that statin monotherapy would lead to the complete dissolution of gallstones [11]. In accordance with this finding, the need of surgery of any type or the cholelithiasis outcomes did not differ between the statin and non-statin groups, which contrasted with some previous studies. In a Taiwanese study, the investigators did not find a beneficial association between statin use and gallstone disease [21]. However, in East Asia, there is a lower prevalence of gallstones, and the stones primarily have a brown pigment, which indicates that they are comprised mainly of calcium [1].

                    Statins were not associated with a lower total serum bilirubin level in our study. In 2011, Ong et al. published a contrasting finding. They investigated whether statins in routine use increase the total bilirubin levels in subjects at high cardiovascular risk; but unexpectedly, the authors found that statin use was associated with lower total bilirubin levels. They suggested that this result could be explained, at least partially, by the effect of statins on glycemia and LDL cholesterol [22].

                    The clinical outcomes did not differ significantly between the study groups, except for the laparoscopic operation time. A shorter laparoscopic operation time was unexpected, as these patients more often have heart disease or hypertension. Conversely, the patients with cardiac disorders used more medications, thereby affecting the bleeding cascade, which would predispose them to bleeding complications. On average, more bleeding was observed among non-users compared with users during laparoscopic operations, but the difference remained statistically insignificant with a p value of 0.07. However, this finding is in line with the shorter operation time among statin users. Possible mechanisms behind these findings may include smaller size of cholesterol particles and gallstones. More research with larger sample sizes is warranted to confirm these findings. The two-year mortality rate (the study time mortality) was also similar among the statin users and non-users. Four patients died in the hospital. Longer observation time mortality was not studied in this study.

                    The mechanism by which statins might shorten the operation time or diminish bleeding remains unknown and requires further study. There were no differences in the perioperative procedures between the groups, and the same surgical team was in charge of their treatment. There is evidence that statins might have relevant anti-inflammatory effects independent of their lipid lowering ability [23].

                    The factors that contribute to supersaturating cholesterol in bile and to the formation of cholesterol gallstones are multifactor. Major sources of cholesterol for biliary secretion are the intestine, liver hepatocytes and circulating lipoproteins. Gallbladder hypomotility, destabilization of bile by kinetic protein factors, abnormal mucins and genetic factors also play roles in cholesterol gallstone disease [24]. Many other factors are associated with cholesterol gallstones formation, such as dietary and life style factors and associated conditions (obesity, estrogen therapy, metabolic syndrome, etc.).

                    Our study had some limitations. Because this study was a retrospective analysis, we could not determine whether the gallstone formation developed before the statin medication was administered. Gallstone formation occurs over a long time period. Furthermore, we do not have accurate data on the patients’ adherence to statin use nor on the duration of the statin treatment in individual patients. Most gallstones are asymptomatic, and the patient does not require a cholecystectomy or hospital admission [25]. In this study, all patients were hospitalized because they had gallstone-related symptoms or complications. We do not have data from the patients with asymptomatic gallstone disease.

                    Conclusion

                    The patients using statins did not have worse outcomes after cholecystectomy than the non-users.

                    We found that statins might shorten laparoscopic surgery time in patients who have symptomatic cholelithiasis. Statin treatment may also be associated with less bleeding during laparoscopic operations. The beneficial effects of statins were observed, although statin use was associated with more comorbidities and patient polypharmacy. A prospective randomized study is needed to show the protective effects of statins on gallbladder surgery.

                    Authors’ information

                    JP MD and PK MD are surgeons in Kuopio University Hospital. HP and ME are Professors of surgery in Eastern Finland University and surgeons in Kuopio University Hospital. VK PhD statistic and HK MD are experts in Finland Medical Association. TK, MP and LK are medical students in Eastern Finland University.

                    Declarations

                    Acknowledgements

                    M.Sc. Tuomas Selander, statistic of Kuopio University Hospital, is gratefully acknowledged for valuable statistical advices. There was no external funding for the study.

                    Authors’ Affiliations

                    (1)
                    Department of Surgery, Kuopio University Hospital
                    (2)
                    School of Medicine, University of Eastern Finland
                    (3)
                    Finnish Medicines Agency

                    References

                    1. Shaffer EA: Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006,20(6):981–996.PubMedView Article
                    2. Russo MW, Wei JT, Thiny MT, Gangarosa LM, Brown A, Ringel Y, Shaheen NJ, Sandler RS: Digestive and liver diseases statistics, 2004. Gastroenterology 2004,126(5):1448–1453.PubMedView Article
                    3. Bodmer M, Brauchli YB, Krahenbuhl S, Jick SS, Meier CR: Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009,302(18):2001–2007.PubMedView Article
                    4. Marschall HU, Einarsson C: Gallstone disease. J Intern Med 2007,261(6):529–542.PubMedView Article
                    5. Schafmayer C, Hartleb J, Tepel J, Albers S, Freitag S, Volzke H, Buch S, Seeger M, Timm B, Kremer B, Folsch UR, Fandrich F, Krawczak M, Schreiber S, Hampe J: Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany. BMC Gastroenterol 2006, 6:36.PubMed CentralPubMedView Article
                    6. Patel J, Abd T, Blumenthal RS, Nasir K, Superko HR: Genetics and Personalized Medicine-a Role in Statin Therapy? Curr Atheroscler Rep 2014.,16(1): 384–013–0384-y 384-013-0384-y
                    7. Squizzato A, Romualdi E, Dentali F, Ageno W: Statins for acute ischemic stroke. Cochrane Database Syst Rev 2011,8(8):CD007551. doi(8):CD007551PubMed
                    8. Ruokoniemi P, Helin-Salmivaara A, Klaukka T, Neuvonen PJ, Huupponen R: Shift of statin use towards the elderly in 1995–2005: a nation-wide register study in Finland. Br J Clin Pharmacol 2008,66(3):405–410.PubMed CentralPubMedView Article
                    9. Cariati A, Piromalli E: Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. Expert Opin Pharmacother 2012,13(9):1223–1227.PubMedView Article
                    10. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Statin use and the risk of cholecystectomy in women. Gastroenterology 2009,136(5):1593–1600.PubMed CentralPubMedView Article
                    11. Wang HH, Portincasa P, de Bari O, Liu KJ, Garruti G, Neuschwander-Tetri BA, Wang DQ: Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur J Clin Invest 2013,43(4):413–426.PubMed CentralPubMedView Article
                    12. Gurusamy KS, Davidson BR: Surgical treatment of gallstones. Gastroenterol Clin North Am 2010,39(2):229–244. viiiPubMedView Article
                    13. Portincasa P, Moschetta A, Palasciano G: Cholesterol gallstone disease. Lancet 2006,368(9531):230–239.PubMedView Article
                    14. Stinton LM, Myers RP, Shaffer EA: Epidemiology of gallstones. Gastroenterol Clin North Am 2010,39(2):157–169. viiPubMedView Article
                    15. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004,80(1):38–44.PubMed
                    16. Festi D, Reggiani ML, Attili AF, Loria P, Pazzi P, Scaioli E, Capodicasa S, Romano F, Roda E, Colecchia A: Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol 2010,25(4):719–724.PubMedView Article
                    17. Banim PJ, Luben RN, Bulluck H, Sharp SJ, Wareham NJ, Khaw KT, Hart AR: The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk). Eur J Gastroenterol Hepatol 2011,23(8):733–740.PubMedView Article
                    18. Suuronen S, Niskanen L, Paajanen P, Paajanen H: Declining cholecystectomy rate during the era of statin use in Finland: a population-based cohort study between 1995 and 2009. Scand J Surg 2013,102(3):158–163.PubMedView Article
                    19. Smith JL, Roach PD, Wittenberg LN, Riottot M, Pillay SP, Nestel PJ, Nathanson LK: Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000,15(8):871–879.PubMedView Article
                    20. Abedin MZ, Narins SC, Park EH, Smith PR, Kirkwood KS: Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci 2002,47(10):2192–2210.PubMedView Article
                    21. Chiu HF, Chen CC, Kuo HW, Lee IM, Wu TN, Yang CY: Statin use and the risk of gallstone disease: a population-based case-control study. Expert Opin Drug Saf 2012,11(3):369–374.PubMedView Article
                    22. Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA: Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999–2008. Atherosclerosis 2011,219(2):728–733.PubMedView Article
                    23. Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005,4(12):977–987.PubMedView Article
                    24. Chuang SC, Hsi E, Lee KT: Genetics of gallstone disease. Adv Clin Chem 2013, 60:143–185.PubMedView Article
                    25. Fujita T: Use of statins and gallstone risk. JAMA 2010,303(12):1146–1147. author reply 1147PubMedView Article
                    26. Pre-publication history

                      1. The pre-publication history for this paper can be accessed here: http://​www.​biomedcentral.​com/​1471-230X/​14/​119/​prepub

                    Copyright

                    © Pulkkinen et al.; licensee BioMed Central Ltd. 2014

                    This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.